78 related articles for article (PubMed ID: 32951068)
1. Overexpression of cyclin F/CCNF as an independent prognostic factor for poor survival in clear cell renal cell carcinoma.
Kwiatkowski M; Krajewski A; Durślewicz J; Buchholz K; Grzanka D; Gagat M; Zabrzyński J; Klimaszewska-Wiśniewska A
Sci Rep; 2024 Apr; 14(1):9280. PubMed ID: 38654021
[TBL] [Abstract][Full Text] [Related]
2. Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma.
Park CK; Heo J; Ham WS; Choi YD; Shin SJ; Cho NH
Cancer Res Treat; 2021 Oct; 53(4):1174-1183. PubMed ID: 33735560
[TBL] [Abstract][Full Text] [Related]
3. CD44 Expression in Clear Cell Renal Cell Carcinoma (ccRCC) Correlates with Tumor Grade and Patient Survival and Is Affected by Gene Methylation.
Papanastasiou AD; Peroukidis S; Sirinian C; Arkoumani E; Chaniotis D; Zizi-Sermpetzoglou A
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790166
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.
Khan R; Pari B; Puszynski K
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes as potential biomarkers in renal cell carcinoma.
Hage Chehade C; Agarwal N
Cancer Cell; 2024 May; 42(5):736-738. PubMed ID: 38670092
[TBL] [Abstract][Full Text] [Related]
6. The oncogene MYBL2 promotes the malignant phenotype and suppresses apoptosis through hedgehog signaling pathway in clear cell renal cell carcinoma.
Yang W; Chen H; Ma L; Wei M; Xue X; Li Y; Jin Z; Dong J; Xiao H
Heliyon; 2024 Mar; 10(6):e27772. PubMed ID: 38510035
[TBL] [Abstract][Full Text] [Related]
7. MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma.
Morris BB; Wages NA; Grant PA; Stukenberg PT; Gentzler RD; Hall RD; Akerley WL; Varghese TK; Arnold SM; Williams TM; Coppola V; Jones DR; Auble DT; Mayo MW
Front Oncol; 2020; 10():585551. PubMed ID: 33489883
[TBL] [Abstract][Full Text] [Related]
8. CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma.
Yang W; Li L; Zhang K; Ma K; Gong Y; Zhou J; Gong K
Epigenomics; 2021 Jan; 13(1):31-45. PubMed ID: 33203244
[No Abstract] [Full Text] [Related]
9. A self-supervised vision transformer to predict survival from histopathology in renal cell carcinoma.
Wessels F; Schmitt M; Krieghoff-Henning E; Nientiedt M; Waldbillig F; Neuberger M; Kriegmair MC; Kowalewski KF; Worst TS; Steeg M; Popovic ZV; Gaiser T; von Kalle C; Utikal JS; Fröhling S; Michel MS; Nuhn P; Brinker TJ
World J Urol; 2023 Aug; 41(8):2233-2241. PubMed ID: 37382622
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma.
Luo G; Wang L; Zheng Z; Gao B; Lei C
Eur J Med Res; 2023 May; 28(1):176. PubMed ID: 37189176
[TBL] [Abstract][Full Text] [Related]
11. E2F2 promotes lung adenocarcinoma progression through B-Myb- and FOXM1-facilitated core transcription regulatory circuitry.
Du K; Sun S; Jiang T; Liu T; Zuo X; Xia X; Liu X; Wang Y; Bu Y
Int J Biol Sci; 2022; 18(10):4151-4170. PubMed ID: 35844795
[TBL] [Abstract][Full Text] [Related]
12. B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2.
Fan X; Wang Y; Jiang T; Liu T; Jin Y; Du K; Niu Y; Zhang C; Liu Z; Lei Y; Bu Y
Oncogene; 2021 Sep; 40(37):5613-5625. PubMed ID: 34316028
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
14. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
16. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Jonasch E; Walker CL; Rathmell WK
Nat Rev Nephrol; 2021 Apr; 17(4):245-261. PubMed ID: 33144689
[TBL] [Abstract][Full Text] [Related]
17. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
18. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
